HSP90B2P and atrial fibrillation: Based on this, HSP inducers (e.g., GGA-59) can accelerate the structural and functional recovery of cardiomyocytes, while NAD+ supplements (as demonstrated in clinical trials such as the HF-AF ENERGY trial) have shown efficacy in reducing AF burden (Kishore et al., 2023).